Exact Therapeutics AS
OSE:EXTX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Exact Therapeutics AS
Research & Development
Exact Therapeutics AS
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
Exact Therapeutics AS
OSE:EXTX
|
Research & Development
-kr25.2m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hofseth Biocare ASA
OSE:HBC
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
U
|
Ultimovacs ASA
OSE:ULTI
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
L
|
Lytix Biopharma AS
OSE:LYTIX
|
Research & Development
-kr72.6m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
N/A
|
|
|
Arcticzymes Technologies ASA
OSE:AZT
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
T
|
Thor Medical ASA
OSE:TRMED
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Exact Therapeutics AS
Glance View
EXACT Therapeutics AS is a clinical stage biopharmaceutical company, which engages in the research and development of novel platform for ultrasound mediated therapeutic amplification. The company is headquartered in Oslo, Oslo and currently employs 8 full-time employees. The company went IPO on 2020-07-14. ACT sonoporation is an approach to ultrasound-mediated, targeted drug enhancement with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within cancer (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. The firm's purpose is to extend and enrich patient lives through targeted therapeutic enhancement. The company is done through harnessing the power of ultrasound in combination with ACT formulation.
See Also
What is Exact Therapeutics AS's Research & Development?
Research & Development
-25.2m
NOK
Based on the financial report for Dec 31, 2024, Exact Therapeutics AS's Research & Development amounts to -25.2m NOK.
What is Exact Therapeutics AS's Research & Development growth rate?
Research & Development CAGR 3Y
-24%
The average annual Research & Development growth rates for Exact Therapeutics AS have been -24% over the past three years .
